Out in NEJM - results of FOENIX-CCA2 study of Futibatinib in #patients with pretreated #CholangioCarcinoma ✅103 #patients ➡️42% ORR 🤩 Median duration of response 9.7 months. 🤩PFS 9.0 months & OS 21.7 months. OncoAlert 🚨#PrecisionMedicine nejm.org/doi/full/10.10…

Preview of the future for loco regional dMMR/MSI-high #GEA by Filippo Pietrantonio at #GI23 ASCO OncLive.com. Needs to test our non-met patients. INFINITY trial. Nice design.

So important to understand MMR/MSI testing, to have experienced pathologists and a correct interpretation by clinicians. Explained by Thierry Andre #GI23

Huge congrats Jenny Seligmann and team of foxtrot-study ! We should definitely celebrate here at #GI23 can’t wait to read the manuscript.

The “small Chalabi plot” by Filippo Pietrantonio Results of cohort 1 of the #infinitytrial in MSIhigh resectable gastric cancer by GONO Foundation 🇮🇹. Miss you and #ascogi23 but superproud of these results!

Stephen V Liu, MD JCO Precision Oncology Nathan A. Pennell MD, PhD, FASCO Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study sciencedirect.com/science/articl…

S1815 is an important ‘negative’ 1L BTC study #GI23 ASCO -ph2 GCN mOS 19m -ph3 GCN mOS 14m with no significant difference to GC standard w/ ⬆️ toxicity ➡️ thanks to Rachna Shroff, MD, MS, FASCO etal for reminding us why we need to do phase 3 trials even in uncommon cancers 🙏 OncoAlert

Rapid abstract session: bot+bal in pMMR/MSS mCRC. ORR 23%, durable responses. Exciting data, colitis/diarrhea rate 21% grade 3-4 with 1-2mg/kg anti-CTLA4. Anthony El-Khoueiry Agenus #GI23

Nice work Filippo Pietrantonio and others. Out now in Clinical Cancer Research HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial aacrjournals.org/clincancerres/…

🔥 AtezoTRIBE: OS data for FOLFOXIRI + Bev vs FOLFOXIRI + AtezoBev in 1st line #mCRC #ASCO23 🔎RAS mut 71%/74%, BRAF mut 14%/8, TMBhigh 10%/12%, high IS IC 32%/32% 👉mPFS 11.5 vs 13.1 mo 👉mPFS2: 19.9 vs 22.6 mo 👉mOS 27.2 vs 33 mo ✅ Benefit for IS IC-high and/or TMB high pMMR

CRC oral session on the updated and OS results of the AtezoTRIBE study by GONO. Again confirmation that Immunoscore IC is able to select patients with immunesensitive pMMR/MSS mCRC and PFS/OS benefit from the addition of atezo to FOLFOXIRI/bev. carlottanto Chiara Cremolini

Fantastic talk by Filippo Pietrantonio on MSI-H/dMMR esophagogastric cancers. I encourage everybody to rewatch! #WCGIC2023 ESMO - Eur. Oncology

GONO Foundation

🔥Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients #ESMO23 ✅PEGASUS phs-II, 135 pts 👉Post-OP ctDNA: 35/135 pts (26) 👉ctDNA+ w/ increased risk of relapse, HR 4.37 👉Seroconversion in 40% of LB+ 👉Promising benefit for LB

First results of the CM8HW are out! Nivo/ipi vs chemo in 1st line dMMR mCRC. We knew it would be positive, but wow 🤯 HR 0.21 for PFS and + across all subgroups. No crossing of the curves! Toxicity very manageable (don’t be scared of low dose ipi1).

Great to have another option for patients. Kohei shitara Manish A. Shah ILSON David @FlorianLordick Sara Lonardi and many others. FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma onclive.com/view/fda-appro… via @onclive

Nice to see CM8HW in press! NEJM 📌 n=303 centrally confirmed dMMR mCRC 1L ➡️ 2y PFS 72% nivo-ipi vs 14% chemo 🌟 Per earlier BMS release, combo is superior to nivo arm but awaiting data - in whom? by how much? toxicity diff? ❓How do we identify pts w/dMMR mCRC who may still

Tremelimumab & durvalumab as neoadjuvant or definitive management of dMMR/MSI GC or GEJ adenocarcinoma Annals of Oncology doi.org/10.1016/j.anno… 🔎 INFINITY by GONO 👉pCR: 60%; MPR 80%; 24-mo PFS 85% & OS 92% 👉76% cCR > NOM 🧐excellent efficacy for chemo-free T300/D ESMO - Eur. Oncology

A successful trial by GONO Foundation , a brilliant effort of academic research. Congrats Filippo Pietrantonio and team!!!

#ESMO25 #CRCsm Honoured to serve as Discussant for CM8HW and BREAKWATER data updates today 🎤 Congrats to Scott Kopetz Dr. Sara Lonardi & pts…slowly but surely, Precision Oncology has arrived for mCRC 🎯 ESMO - Eur. Oncology OncoAlert #ESMOAmbassadors